Thiazolidinediones (TZDs) are established therapies for T2D that enhance insulin sensitivity in adipose tissue, skeletal muscle, and liver, and promote the re-distribution of fat from the liver and skeletal muscle to adipocytes. Here, INS is linked to type 2 diabetes mellitus.